These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1869342)

  • 61. Disposition of minoxidil in patients with various degrees of renal function.
    Halstenson CE; Opsahl JA; Wright CE; Fleishaker JC; Andreadis NA; Sobieraj J; Matzke GR
    J Clin Pharmacol; 1989 Sep; 29(9):798-802. PubMed ID: 2808745
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment.
    Weller S; Jones LS; Lou Y; Peppercorn A; Ng-Cashin J
    Antimicrob Agents Chemother; 2013 Jul; 57(7):2967-71. PubMed ID: 23587959
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sotalol kinetics in renal insufficiency.
    Blair AD; Burgess ED; Maxwell BM; Cutler RE
    Clin Pharmacol Ther; 1981 Apr; 29(4):457-63. PubMed ID: 7471612
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance.
    Payton CD; Fox JG; Pauleau NF; Boulton-Jones JM; Ioannides C; Johnston A; Thomas P
    Eur Heart J; 1987 Dec; 8 Suppl M():15-22. PubMed ID: 2897297
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetics of tocainide in patients with severe renal failure.
    Braun J; Sörgel F; Engelmaier F; Gluth WP; Gessler U
    Eur J Clin Pharmacol; 1985; 28(6):665-70. PubMed ID: 3933983
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.
    Bressolle F; Brès J; Mourad G
    Clin Pharmacokinet; 1989 Nov; 17(5):367-73. PubMed ID: 2582694
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of effect of impaired renal function on lamivudine pharmacokinetics.
    Bouazza N; Tréluyer JM; Ghosn J; Hirt D; Benaboud S; Foissac F; Viard JP; Urien S
    Br J Clin Pharmacol; 2014 Oct; 78(4):847-54. PubMed ID: 24750102
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetics of amikacin in patients with impaired renal function.
    McHenry MC; Wagner JG; Hall PM; Vidt DG; Gavan TL
    J Infect Dis; 1976 Nov; 134 SUPPL():S343-8. PubMed ID: 993627
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function.
    Movin-Osswald G; Boelaert J; Hammarlund-Udenaes M; Nilsson LB
    Br J Clin Pharmacol; 1993 Jun; 35(6):615-22. PubMed ID: 8329289
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetics of gabapentin in subjects with various degrees of renal function.
    Blum RA; Comstock TJ; Sica DA; Schultz RW; Keller E; Reetze P; Bockbrader H; Tuerck D; Busch JA; Reece PA
    Clin Pharmacol Ther; 1994 Aug; 56(2):154-9. PubMed ID: 8062491
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure.
    Rodondi LC; Flaherty JF; Schoenfeld P; Barriere SL; Gambertoglio JG
    Clin Pharmacol Ther; 1989 May; 45(5):527-34. PubMed ID: 2721108
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
    Drusano GL; Weir M; Forrest A; Plaisance K; Emm T; Standiford HC
    Antimicrob Agents Chemother; 1987 Jun; 31(6):860-4. PubMed ID: 3619418
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
    Johnston A; Henry JA; Warrington SJ; Hamer NA
    Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency.
    Kelloway JS; Awni WM; Lin CC; Lim J; Affrime MB; Keane WF; Matzke GR; Halstenson CE
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2267-74. PubMed ID: 1803999
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics of carumonam in patients with renal insufficiency.
    Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
    Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.
    Shyu WC; Morgenthien EA; Barbhaiya RH
    Br J Clin Pharmacol; 1996 May; 41(5):397-402. PubMed ID: 8735680
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment.
    Halstenson CE; Triscari J; DeVault A; Shapiro B; Keane W; Pan H
    J Clin Pharmacol; 1992 Feb; 32(2):124-32. PubMed ID: 1613121
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Isepamicin disposition in subjects with various degrees of renal function.
    Halstenson CE; Kelloway JS; Affrime MB; Lin CC; Teal MA; Shapiro BE; Awni WM
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2382-7. PubMed ID: 1804011
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of renal impairment on the pharmacokinetics of cibenzoline.
    Massarella JW; Khoo KC; Aogaichi K; Di Persio D; Smith M; Kluger J; Chow MS
    Clin Pharmacol Ther; 1988 Mar; 43(3):317-23. PubMed ID: 3345622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.